Transforming the treatment of pulmonary hypertension
First purpose-built, minimally invasive, ultrasound-based system designed to treat patients with pulmonary hypertension.
Clinical Need
Large unmet clinical need in a patient population with significant symptoms and increased morbidity and mortality
As many as two-thirds of heart failure patients around the world have pulmonary hypertension, which is shown to lead to on-going symptoms and an increased risk of mortality and hospitalization despite treatment of the underlying heart failure. This is especially concerning in pulmonary hypertension due to left heart disease (Group 2), as there are no approved drug or device therapies for this group of pulmonary hypertension patients.
Solution
Addressing the complications of pulmonary hypertension with pulmonary artery denervation (PADN)
The Gradient Denervation System is a novel technology intended to treat patients with pulmonary hypertension. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques.